Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Last close ₹442.95down ₹9.00 (1.99%)BSE ₹449.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
52-week range of traded prices to 23 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals share news and announcements
637 announcements, routine notices left out, newest first. Page 13 of 13.
Mar 2011
15 Mar · Board Meeting on Mar 17, 2011
Meeting of the Board of Directors of the Company will be held on March 17, 2011: 1. - To consider the allotment of 15,00,000 equity ....
Feb 2011
Jan 2011
25 Jan · Business
With reference to the earlier announcement dated January 25, 2011 regarding Udyog Rattan Award and Excellence Award from the Institute of Economics Studies Delhi, Bafna Pharmaceuticals ....25 Jan · Business
Company has received Udyog Rattan Award and Excellence Award from Mr. Korn Dabbaransi, former Deputy Prime Minister of Thailand held ....18 Jan · Business
Company has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of ....
Dec 2010
6 Dec · Board meeting
Board of Directors of the Company at its meeting held on December 06, 2010, inter alia, has transacted the business of further issue ....2 Dec · Board Meeting on Dec 06, 2010
Meeting of the Board of Directors of the Company will be held on December 06, 2010, inter alia, to consider the matter of issue and allotment ....
Nov 2010
22 Nov · UK MHRA approval for FINASTERIDE 5 MG TABLETS
Product “FINASTERIDE 5 MG TABLETS “ has got UK Medicines and Healthcare products Regulatory Agency (MHRA) approval.15 Nov · UK MHRA approval for AMLODIPINE 5 MG & AMLODIPINE 10 MG TABLETS
Company's product "AMLODIPINE 5 MG & AMLODIPINE 10 MG TABLETS" has got UK Medicines and Healthcare products Regulatory Agency (MHRA) approval.10 Nov · GHANA FDB approval of ATENOLOL 50 & 100 MG TABLETS
Company's product “ATENOLOL 50 & 100 MG TABLETS“ has got Ghana FOOD & DRUGS BOARD approval.
Oct 2010
19 Oct · FDA approval for diabetes drug "METFORMIN 500 MG TABLET"
Company's product "METFORMIN 500 MG TABLET" has got Ghana FDA approval.
Sep 2010
7 Sep · "TGA approval" from Australia Regulators for Bafna facility
Company has got "TGA approval" (Australia), which will enable the Company to market its products in Australia.
Aug 2010
Jul 2010
28 Jul · Meeting
Register of Members & Share Transfer Books of the Company will remain closed from August 21, 2010 to August 23, 2010 (both days inclusive) ....19 Jul · Clarifies on news item
With reference to the news item appearing in a leading financial daily titled "Bafna Pharma close to sealing UK Buy", Bafna Pharmaceuticals Ltd has clarified to BSE that the news report ....13 Jul · Updates
Mr. Bafna Mahaveer Chand, Chairman & Managing Director, Bafna Pharmaceuticals ltd., has been awarded by Mr. C. B. Bhave, Chairman, SEBI, ....6 Jul · Approval of CLONAZEPAM 0.5 MG AND CLONAZEPAM 2 MG TABLETS
Product "CLONAZEPAM 0.5 MG and CLONAZEPAM 2 MG TABLETS" has got Site approval from MHRA UK.
Jun 2010
3 Jun · Approval of PARACETAMOL 500 MG TABLET, PARACETAMOL CAPLET and LOPERAMIDE 2 MG CAPSULE
Company's product "PARACETAMOL 500 MG TABLET, PARACETAMOL CAPLET and LOPERAMIDE 2 MG CAPSULE" has got Site approval from MHRA UK.
May 2010
29 May · Board meeting
Board of Directors of the Company at its meeting held on May 28, 2010, inter alia, has transacted the following: 1. Decided Not ....25 May · Ethopian approval for Grantlyon Facility
Company's facility has been approved with compliance of Good Manufacturing Practice by Ethopian audit team. The Drug Administration and Control ....21 May · Board meeting
Meeting of the Board of Directors of the Company will be held on May 28, 2010, inter alia, to consider the following business: 1. ....12 May · Board meeting
Board of Directors of the Company at its meeting held on April 26, 2010, inter alia, has transacted the following: 1. Re-appointment ....
Apr 2010
30 Apr · Results
Company has decided to consider the Audited results for the financial year ended March 31, 2010.
Feb 2010
23 Feb · Bafna Pharmaceuticals - Approval Clarithromycin 500 mg from MHRA UK
Company's product "Clarithromycin 500 mg" has got Site approval from MHRA UK on February 11, 2010 Vide their letter No. PL/15764/0040-0003.22 Feb · Bafna Pharmaceuticals - Approval Clarithromycin 250 mg from MHRA UK
Company's product "Clarithromycin 250 mg" has got site approval from MHRA UK on February 11, 2010 Vide their letter No. PL/15764/0039-0003.
Jan 2010
18 Jan · Business
Company have been awarded the Gold Quality Excellence Award 2009 (Turnover between 25 Crores to 75 Crores) from Indian Drug Manufacturers ....14 Jan · Bafna Pharmaceuticals - Approval Simvastatin 20mg from MHRA UK
Company's product "SIMVASTATIN20MG" has got approval from MHRA UK on December 29, 2009.11 Jan · Bafna Pharmaceuticals - Approval Simvastatin 10mg from MHRA UK
Company's product "SIMVASTATIN 10MG" has got approval from MHRA UK on December 29, 2009.6 Jan · Bafna Pharmaceuticals - Approval Clonidine Hcl 0.25mg from MHRA UK
Company's product "CLONIDINE HCL 0.25 mg" has got approval from MHRA UK on December 11, 2009.